PubMed COVID-19 Clinical Care

CONCLUSIONS: COVID-19 infection is an independent predictor of mortality in adults hospitalized with NVUGIB.

CONCLUSIONS: By linking administrative and clinical databases, we characterized the burden of the COVID-19 pandemic in Madrid over 3 years. Our analysis proposes a high-level framework for comparisons of the burden of COVID-19 across areas worldwide.

Surveillance is essential to inform evidence-based policy and control measures that combat antimicrobial resistance (AMR). The Canadian Nosocomial Infection Surveillance Program (CNISP) collaborates with 88 sentinel hospitals across Canada to conduct

CONCLUSION: We experienced a primary renal peripheral T-cell lymphoma, not otherwise specified that was followed up without treatment after surgery.

Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory coronavirus-2 (SARS-CoV-2). Several explanations for the development of cardiovascular complications during and after acute COVID-19 infection have been hypothesized

Immunoglobulin (IG) replacement products are used routinely in patients with immune deficiency and other immune dysregulation disorders, who have poor immune responses to vaccination and require passive immunity conferred by commercial antibody

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID-19, but the effect of treatment during acute infection on risk of Long COVID is unknown. We hypothesized that nirmatrelvir treatment during acute SARS-CoV-2 infection reduces risk

With the widespread vaccination of COVID-19 vaccine, a few cases have been reported that COVID-19 vaccine may cause endocrine disorders. A 59-y-old man presented with a loss of appetite after the first COVID-19 vaccination, which resolved

Purpose: Favipiravir used against COVID-19 is an antiviral drug that causes adverse reactions such as hyperuricemia, liver damage and hematopoetic toxicity. The aim of the study was to investigate the systemic and ocular side-effects of favipiravir

We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in